🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The use of tumor markers taken pre-orchiectomy can lead to a wrong igcccg classification of germ cell cancer patients... pubmed.ncbi.nlm.nih.gov/37392170/

🥂👏 Christoph Seidel congratulations 🥇for winning the #BestPoster award #testicular&Penile cancers and getting the Rosette! #ESMO2023 ESMO - Eur. Oncology Elizabeth Plimack MD Axel Bex #HDCT #germcelltumors

Aaron E. Lisberg, presenting data from the TROPON-LUNG01 study during the Presidential Symposium 3 at the ESMO Congress 2023. Another 2nd line trestment trial failed to show OS benefit against DOCETAXEL MONO. Docetaxel mono is not really standard of care in NSCLC...

Great one Vinay + great audience!!👍👍

The BNT211 Phase I data now published in Nature Medicine show a very effective and promising activity of CAR-T cells in solid tumors with Claudin 6 expression. The majority of patients had relapsed and refractory germ cell cancer patients. nature.com/articles/s4159…

☢️🦴 In a multi-center RCT ⚖️ (n=78), radiation to high-risk asymptomatic bone metastases ⬇️ skeletal-related events and prolonged overall survival in metastatic solid tumors: brnw.ch/21wE43a #radonc Erin Gillespie, MD MPH

Best of both worlds for seminoma. Avoid intense and long chemo. Avoid large field XRT. Single cycle of carbo and small field XRT for stage IIA/B. #radonc

#urologie Forschende um Felix Bremmer (Uni Göttingen) und Daniel Nettersheim (Daniel Nettersheim & Uniklinik Düsseldorf) entschlüsseln möglicher Weg der Therapieflucht in Hodentumore. Wir förderten das Projekt mit 375.000 €. 👉Die ganze PM: wilhelm-sander-stiftung.de/neues/

This trial demonstrates non-inferiority of tislelizumab agains sorafenib in unresectabe 1st l. HCC ➡️ why against SO, which is no standard of care? ➡️ why a non-inferiority trial against SO, which performed bad in the real life setting acoording SEER? jamanetwork.com/journals/jamao…

➡️Regarding germline genetic basis, TGCTs have a high heritability among all cancers ➡️CHK2, was shown to be strongly enriched in TGCT cohorts ➡️This study from the Hamburg cohort confirmed TGCT cases harboring CHK2 mdpi.com/2558260 #mdpijcm via JCM MDPI

Cisplatin treatment associated with attenuated biventricular systolic function and myocardial tissue alterations. Check out our new paper Long-term cardiotoxicity in germ cell cancer survivors after platinum-based chemotherapy: cardiac MR shows impaired… pubmed.ncbi.nlm.nih.gov/37982836/

"well-tolerated" "tolerable" "manageable" "acceptable" those minimizing terms were not associated with grade 3 or 4 adverse events rates ❗️ ➡️patients should decide what is "acceptable" or not based on events rate and PRO ! Very important work from Manni Mohyuddin and col 👏!👇

Ever seen a Seminoma Patient with excessively high hCG levels, so that chorionic features are suspected? We worked up Patients with hCG levels >1000 U/l at first diagnosis finding a subtpye of pure Seminoma with Syncytiotrophoblasts pubmed.ncbi.nlm.nih.gov/38097681/

"Out now: High dose CTX offers curative potential and is feasible if conducted after conventional dosed salvage regimens in r/r GTC pts. The 5-year OS rate is 37% compared to 63% when HD is used as first salvage regimen. Therefore always consider HD-CTX". esmoopen.com/article/S2059-…

Anybody using the ipfsg update calculator in the clinic on a regular basis?This calculation for example shows a rather low Pfs still for a „good prognosis“ constellation with NS. What to do with it?

Today we saw a 30 year old male with the new diagnosis of recurrent metastatic germ cell cancer. He has a history of prior severe anaphylactic reaction to etoposide. What salvage treatment would you suggest? 4xTIP or seq. HD-CE changing etoposide to etoposide phosphate?

Great work by EBMT collaboration 💪strengthen the importance of high dose chemotherapay in patients with PMNSGCTs just published EBMT - ESMO Open esmoopen.com/article/S2059-…

New RWE data on the GMALL 2002 protocol in adult Burkitt lymphoma: In a retrospective study of 48 pts, ORR was 81.6% with 3y-PFS/OS of 73%. High toxicity, but no grade 5 events. Burkitt leukemia & BM involvement = adverse factors. Further trials needed. clinical-lymphoma-myeloma-leukemia.com/article/S2152-…